|
Malignant tumor of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we provide procedures for the insertion of the RRM2-C2orf48 fusion ORF into a mammalian expression vector, achieving the overexpression of the RRM2-C2orf48 fusion protein in a colon cancer cell line by retroviral transduction.
|
31728969 |
2020 |
|
Adenocarcinoma of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, by testing genes shared by several functional gene-signatures for their association with event-free survival in a validation cohort (n = 272), we identified five genes (ASPN, BGN, COL1A1, RRM2 and TYMS)-three of which are included in commercially available prognostic tests-whose high expression was significantly associated with worse outcome exclusively in T2E-negative PCa.
|
31732966 |
2020 |
|
Colon Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we provide procedures for the insertion of the RRM2-C2orf48 fusion ORF into a mammalian expression vector, achieving the overexpression of the RRM2-C2orf48 fusion protein in a colon cancer cell line by retroviral transduction.
|
31728969 |
2020 |
|
Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Then, the effect of RRM2 inhibition on renal cell carcinoma (RCC) growth using siRNA or Triapine, an RRM2-specific inhibitor, was characterized in RCC cell lines.
|
31118677 |
2019 |
|
Fibrosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The dual luciferase reporter assay confirmed that piR-39980 promotes apoptosis and inhibits proliferation in fibrosarcoma by repressing RRM2 through direct targeting at its 3'UTR through extensive sequence complementary binding, unlike microRNA targeting.
|
30362638 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, RRM2 gene can be considered as a potential therapeutic target in the clinical treatment of CML.
|
31233186 |
2019 |
|
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Silencing RRM2 inhibits multiple myeloma by targeting the Wnt/β‑catenin signaling pathway.
|
31322175 |
2019 |
|
Sexually Transmitted Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Taken together, these preclinical results provide new insights into the immune mechanisms of protection against recurrent genital herpes and promote the tegument RR2 protein as a viable candidate Ag to be incorporated in future genital herpes therapeutic mucosal vaccines.<b>IMPORTANCE</b> Recurrent genital herpes is one of the most common sexually transmitted diseases, with a global prevalence of HSV-2 infection predicted to be over 536 million worldwide.
|
30787156 |
2019 |
|
Lymphoma, T-Cell, Cutaneous
|
0.010 |
Biomarker
|
disease |
BEFREE |
Resistant CTCL exhibited high levels of histone acetylation, which correlated with increased expression of 338 genes (FDR < 0·05), including some novel to CTCL: BIRC5 (anti-apoptotic); RRM2 (cell cycle); TXNDC5, GSTM1 (redox); and CXCR4, LAIR2 (cell adhesion/migration).
|
31358475 |
2019 |
|
Agenesis of corpus callosum
|
0.010 |
Biomarker
|
disease |
BEFREE |
Pharmacological and siRNA-mediated inhibition of RRM2 blocks cell proliferation, induces apoptosis and inhibits cell migration, suggesting that it may be an interesting target in ACC.
|
31363169 |
2019 |
|
Adult Fibrosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The dual luciferase reporter assay confirmed that piR-39980 promotes apoptosis and inhibits proliferation in fibrosarcoma by repressing RRM2 through direct targeting at its 3'UTR through extensive sequence complementary binding, unlike microRNA targeting.
|
30362638 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> The current results provided evidence that RRM2 might act as a novel target for ccRCC, and exploration of nonnucleoside, reversible, small-molecule inhibitors against RRM2 could be promising.
|
31118677 |
2019 |
|
Aplasia Cutis Congenita
|
0.010 |
Biomarker
|
disease |
BEFREE |
Pharmacological and siRNA-mediated inhibition of RRM2 blocks cell proliferation, induces apoptosis and inhibits cell migration, suggesting that it may be an interesting target in ACC.
|
31363169 |
2019 |
|
Recurrent genital herpes simplex
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these preclinical results provide new insights into the immune mechanisms of protection against recurrent genital herpes and promote the tegument RR2 protein as a viable candidate Ag to be incorporated in future genital herpes therapeutic mucosal vaccines.<b>IMPORTANCE</b> Recurrent genital herpes is one of the most common sexually transmitted diseases, with a global prevalence of HSV-2 infection predicted to be over 536 million worldwide.
|
30787156 |
2019 |
|
Papillary Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A 3-mRNA signatures consisting of ERG, RRM2, and EGF was constructed to predict survival in pRCC.
|
31348324 |
2019 |
|
Rheumatoid Arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the present study, a cell permeable peptide‑conjugated liposome‑polycation‑DNA (LPD) complex loaded with RRM2 small interfering RNA (siRNA) (CCP‑LPDR) was developed, aiming to increase the levels of apoptosis and inhibit the proliferation of RA‑FLS.
|
30106091 |
2018 |
|
Squamous cell carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Finally, gemcitabine sensitization mediated by autophagy induction through GW8510-caused RRM2 down-regulation was demonstrated <i>in vivo</i> in gemcitabine-resistant LSCC tumor xenograft, further indicating that the sensitization is dependent on autophagy activation.
|
29853661 |
2018 |
|
Pancreatic adenocarcinoma resectable
|
0.010 |
Biomarker
|
disease |
BEFREE |
Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
|
28196013 |
2018 |
|
Liver Cirrhosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
CDK1, PBK, RRM2, and ASPM may be key genes for HCC transformation from cirrhosis.
|
28640074 |
2017 |
|
Rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Importantly, human double minute 2 inhibitor nutlin-3 decreased RRM1 and RRM2 in TP53 wild type rhabdomyosarcoma Rh18 but not in TP53 mutated Rh30 cells.
|
28507282 |
2017 |
|
Follicular thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the identified APLP2, RRM2, and PRC1 signature could be useful for distinguishing between benign (FA) and malignant (FTC and FVPTC) tumors of the thyroid follicular epithelium.
|
27796194 |
2017 |
|
Childhood Rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Importantly, human double minute 2 inhibitor nutlin-3 decreased RRM1 and RRM2 in TP53 wild type rhabdomyosarcoma Rh18 but not in TP53 mutated Rh30 cells.
|
28507282 |
2017 |
|
Adult Rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Importantly, human double minute 2 inhibitor nutlin-3 decreased RRM1 and RRM2 in TP53 wild type rhabdomyosarcoma Rh18 but not in TP53 mutated Rh30 cells.
|
28507282 |
2017 |
|
Malignant Peripheral Nerve Sheath Tumor
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PLK1, RRM1, and RRM2 mRNA levels were increased in MPNST compared to benign neurofibroma tissue, and the protein level of PLK1 was increased in the MPNST cell lines compared to normal Schwann cells, indicating an increased dependence on these drug targets in malignant cells.
|
28556483 |
2017 |
|
Cirrhosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
CDK1, PBK, RRM2, and ASPM may be key genes for HCC transformation from cirrhosis.
|
28640074 |
2017 |